Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Neoplasm Malignant|Epithelial Ovarian Cancer|Triple Negative Breast Cancer|Hormone Receptor Positive Breast Carcinoma|Metastatic Castration-resistant Prostate Cancer
Interventions: DRUG: XL102|DRUG: Fulvestrant|DRUG: Abiraterone|DRUG: Prednisone
Sponsor: Exelixis